Avoro Capital Advisors LLC Trims Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Avoro Capital Advisors LLC lowered its position in Kura Oncology, Inc. (NASDAQ:KURA) by 8.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,541,505 shares of the company’s stock after selling 308,495 shares during the period. Kura Oncology makes up approximately 1.0% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 25th largest holding. Avoro Capital Advisors LLC’s holdings in Kura Oncology were worth $72,920,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Kura Oncology during the 1st quarter valued at approximately $110,000. Cape Investment Advisory Inc. acquired a new position in Kura Oncology during the fourth quarter valued at $176,000. Saxon Interests Inc. acquired a new position in Kura Oncology during the first quarter valued at $201,000. Entropy Technologies LP purchased a new stake in Kura Oncology in the first quarter valued at $218,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Kura Oncology by 81.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,617 shares of the company’s stock worth $333,000 after purchasing an additional 7,027 shares during the period.

Kura Oncology Trading Down 0.6 %

Shares of NASDAQ:KURA opened at $20.95 on Monday. The business’s 50 day moving average price is $20.25 and its 200-day moving average price is $20.61. Kura Oncology, Inc. has a 1 year low of $7.41 and a 1 year high of $24.17. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -9.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. Kura Oncology’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.53) EPS. On average, equities research analysts forecast that Kura Oncology, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on KURA shares. Stifel Nicolaus lowered their target price on Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.60.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.